Cross-Sector entity
Of the tracked stories, 3 of 6 also mention Mereo BioPharma Group plc, the most common co-covered peer. Across an 8-day span, the pace is roughly 5.3 stories per week. The busiest single day carried 3. The clearest coverage concentration is corporate-law: 2 of 6 stories, with the rest divided among 3 other categories.
6 verified stories tracked
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 6 also mention Mereo BioPharma Group plc, the most common co-covered peer. Across an 8-day span, the pace is roughly 5.3 stories per week. The busiest single day carried 3. The clearest coverage concentration is corporate-law: 2 of 6 stories, with the rest divided among 3 other categories. Each carries 3 original sources on average. This profile follows 6 Cross-Sector stories mentioning Ultragenyx Pharmaceutical Inc. across the period from March 5, 2026 to March 12, 2026. Negative sentiment appears in 0% of the tracked stories.
Computed from the 6 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ultragenyx Pharmaceutical Inc.. Shared-story counts are live from our verified record — not editorial picks.
Motion to Dismiss Phase
Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements.
Discovery Phase Begins
Courts likely to rule on motions to dismiss, leading to the exchange of internal corporate documents.
Lead Counsel Appointment
Expected timeframe for the court to designate the lead plaintiff and legal representation.
Lead Plaintiff Deadline
Final day for affected investors to petition the court to lead the class action.
Lead Plaintiff Deadline
Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases.
Lawsuit Announcements
Schall Law Firm files class action notices for Soleno Therapeutics and Ultragenyx Pharmaceutical.
Litigation Commencement
Schall Law Firm announces class action lawsuits against both SLNO and RARE.
Market Reaction
Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN.
Investor Alerts Issued
Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies.
Coordinated Legal Alerts
Pomerantz Law Firm issues a series of reminders for class action deadlines across four major firms.
Soleno Executive Turnover
Official filing confirms the departure of several directors and officers.
Soleno Financial Results
Soleno files annual results and operational updates.
Ultragenyx Restructuring Disclosure
Company files SEC report detailing costs for exit or disposal activities.
The Schall Law Firm has initiated securities fraud class action lawsuits against biotech players Soleno Therapeutics and Ultragenyx Pharmaceutical. The legal actions follow a series of corporate disclosures in early 2026, inviting impacted investors to lead the litigation efforts.
The Schall Law Firm has initiated securities fraud class action lawsuits against rare disease biotechs Soleno Therapeutics and Ultragenyx Pharmaceutical. These legal challenges highlight the heightened scrutiny on clinical data transparency and regulatory communications in the high-stakes orphan drug sector.
The Schall Law Firm has initiated securities fraud class actions against Soleno Therapeutics and Ultragenyx Pharmaceutical, alleging violations of federal securities laws. The firm is currently seeking lead plaintiffs to represent the class in these high-stakes biotech litigations following potential misrepresentations to the market.
Source: prnewswire.com · prnewswire.com
Pomerantz Law Firm has issued urgent reminders for investors regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These legal actions target alleged securities fraud and disclosure failures, setting critical deadlines for lead plaintiff applications.
Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections.
Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.
Source: prnewswire.com · prnewswire.com
